Related Experiment Video
Updated: Feb 13, 2026
A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
Published on: October 24, 2015
Multi-modal gradual fusion transformer-based model for predicting immunotherapy response in patients with
Lushan Xiao1, Jiaren Wang1, Hao Cui1
1Department of Health Management, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Background:
Immunotherapy effectively extends survival in hepatocellular carcinoma (HCC) patients. Predicting immunotherapy responses can inform treatment strategies for HCC. This study aimed to develop multi-modal transformer-based models to predict the immunotherapy response and to validate their performance in an independent cohort.
Materials And Methods:
Patients with HCC from five medical centers were retrospectively included. Clinical features were selected using Least Absolute Shrinkage and Selection Operator method. Multi-modal gradual fusion transformer-based models were trained using clinical features and intra- and peritumoral patches from arterial and portal venous phase computed tomography images in the training cohort. These models were tested on internal validation and external test cohorts. Models' performance and generalization across different modalities were compared.
Results:
Patients from the Hospital 1 were partitioned into a training (n = 209) and an internal validation cohort (n = 90) at a 7:3 ratio. And patients from the other four centers formed an independent external test cohort (n = 85). The number of progressive disease (PD) patients in the training, internal validation, and external test cohorts was 44 (21.1%), 20 (22.2%), and 20 (23.5%), respectively. The model using clinical data, intratumoral imaging, and peritumoral imaging modalities (GIFT-CIP) demonstrated strong predictive performance, achieving an area under the curve (AUC) values of 0.926 (95% CI: 0.892-0.962), 0.911 (95% CI: 0.878-0.946), and 0.883 (95% CI: 0.835-0.935) for training cohort, internal validation cohort, and external test cohort, respectively. Crucially, the GIFT-CIP model effectively stratified patients into low- and high-risk groups, showing significant differences in progression-free survival and overall survival in external test cohort (p < 0.01).
Conclusions:
The GIFT-CIP model is a non-invasive method for predicting immunotherapy responses in patients with HCC. This model may be clinically useful for assisting clinicians in guiding surveillance follow-up and identifying optimal immunotherapy strategies.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
05:31Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Related Concept Videos
01:29Gradually Varying Flow
02:45Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
01:27Tumor Immunotherapy
01:15Sensory Modalities
General senses refer to the broad category of sensory information detected by receptors in the body and can be further grouped into somatic and visceral senses. Somatic sensations include touch, pressure, temperature, and pain and are essential for navigating our environment and...
02:27Predicting Molecular Geometry
01:33Bacterial Transformation
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...